Next Article in Journal
The Ageing Brain: Effects on DNA Repair and DNA Methylation in Mice
Next Article in Special Issue
Influence of microRNAs and Long Non-Coding RNAs in Cancer Chemoresistance
Previous Article in Journal
Type 1 Diabetes Candidate Genes Linked to Pancreatic Islet Cell Inflammation and Beta-Cell Apoptosis
Previous Article in Special Issue
Integrative miRNA-Gene Expression Analysis Enables Refinement of Associated Biology and Prediction of Response to Cetuximab in Head and Neck Squamous Cell Cancer
Open AccessArticle

MicroRNA Expression Profile Identifies High Grade, Non-Muscle-Invasive Bladder Tumors at Elevated Risk to Progress to an Invasive Phenotype

1
Department of Urology, Lahey Hospital and Medical Center, Burlington, MA 01805, USA
2
Department of Urology, Hospital de Clinicas de Porto Alegre, School of Medicine, Universidade Federal do Rio Grande do Sul, Porto Alegre 90035-003, Brazil
3
Cell and Molecular Biology Laboratory, Lahey Hospital and Medical Center, Burlington, MA 01805, USA
4
Biostatistics Research, Institute for Clinical Research Health Policy Studies, Tufts Medical Center, Boston, MA 02111, USA
5
Department of Pathology, University of Wisconsin, Madison, WI 53726, USA
6
Deceased
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work and are listed in alphabetical order.
Academic Editors: J. Peter W. Young and George A. Calin
Genes 2017, 8(2), 77; https://doi.org/10.3390/genes8020077
Received: 28 September 2016 / Revised: 10 January 2017 / Accepted: 11 February 2017 / Published: 17 February 2017
(This article belongs to the Special Issue microRNAs and Other Non-Coding RNAs in Human Diseases)
The objective of this study was to identify a panel of microRNAs (miRNAs) differentially expressed in high-grade non-muscle invasive (NMI; TaG3–T1G3) urothelial carcinoma that progress to muscle-invasive disease compared to those that remain non-muscle invasive, whether recurrence happens or not. Eighty-nine high-grade NMI urothelial carcinoma lesions were identified and total RNA was extracted from paraffin-embedded tissue. Patients were categorized as either having a non-muscle invasive lesion with no evidence of progression over a 3-year period or as having a similar lesion showing progression to muscle invasion over the same period. In addition, comparison of miRNA expression levels between patients with and without prior intravesical therapy was performed. Total RNA was pooled for microarray analysis in each group (non-progressors and progressors), and qRT-PCR of individual samples validated differential expression between non-progressive and progressive lesions. MiR-32-5p, -224-5p, and -412-3p were associated with cancer-specific survival. Downregulation of miR-203a-3p and miR-205-5p were significantly linked to progression in non-muscle invasive bladder tumors. These miRNAs include those implicated in epithelial mesenchymal transition, previously identified as members of a panel characterizing transition from the non-invasive to invasive phenotype in bladder tumors. Furthermore, we were able to identify specific miRNAs that are linked to postoperative outcome in patients with high grade NMI urothelial carcinoma of the bladder (UCB) that progressed to muscle-invasive (MI) disease. View Full-Text
Keywords: microRNA; non-muscle invasive bladder cancer; progression; intravesical therapy microRNA; non-muscle invasive bladder cancer; progression; intravesical therapy
Show Figures

Figure 1

MDPI and ACS Style

Lenherr, S.M.; Tsai, S.; Silva Neto, B.; Sullivan, T.B.; Cimmino, C.B.; Logvinenko, T.; Gee, J.; Huang, W.; Libertino, J.A.; Summerhayes, I.C.; Rieger-Christ, K.M. MicroRNA Expression Profile Identifies High Grade, Non-Muscle-Invasive Bladder Tumors at Elevated Risk to Progress to an Invasive Phenotype. Genes 2017, 8, 77.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map

1
Back to TopTop